Cargando…
Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer
PURPOSES: To evaluate the plan quality and robustness of both dose and dose rate of proton pencil beam scanning (PBS) transmission FLASH delivery in lung cancer treatment. METHODS AND MATERIALS: An in-house FLASH planning platform was used to optimize 10 lung cancer patients previously consecutively...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435957/ https://www.ncbi.nlm.nih.gov/pubmed/36059710 http://dx.doi.org/10.3389/fonc.2022.970602 |
_version_ | 1784781262753366016 |
---|---|
author | Wei, Shouyi Lin, Haibo Huang, Sheng Shi, Chengyu Xiong, Weijun Zhai, Huifang Hu, Lei Yu, Gang Press, Robert H. Hasan, Shaakir Chhabra, Arpit M. Choi, J. Isabelle Simone, Charles B. Kang, Minglei |
author_facet | Wei, Shouyi Lin, Haibo Huang, Sheng Shi, Chengyu Xiong, Weijun Zhai, Huifang Hu, Lei Yu, Gang Press, Robert H. Hasan, Shaakir Chhabra, Arpit M. Choi, J. Isabelle Simone, Charles B. Kang, Minglei |
author_sort | Wei, Shouyi |
collection | PubMed |
description | PURPOSES: To evaluate the plan quality and robustness of both dose and dose rate of proton pencil beam scanning (PBS) transmission FLASH delivery in lung cancer treatment. METHODS AND MATERIALS: An in-house FLASH planning platform was used to optimize 10 lung cancer patients previously consecutively treated with proton stereotactic body radiation therapy (SBRT) to receive 3 and 5 transmission beams (Trx-3fds and Trx-5fds, respectively) to 34 Gy in a single fraction. Perturbation scenarios (n=12) for setup and range uncertainties (5 mm and 3.5%) were introduced, and dose-volume histogram and dose-rate-volume histogram bands were generated. Conventional proton SBRT clinical plans were used as a reference. RTOG 0915 dose metrics and 40 Gy/s dose rate coverage (V(40Gy/s)) were used to assess the dose and dose rate robustness. RESULTS: Trx-5fds yields a comparable iCTV D(2%) of 105.3%, whereas Trx-3fds resulted in inferior D(2%) of 111.9% to the clinical SBRT plans with D(2%) of 105.6% (p<0.05). Both Trx-5fds and Trx-3fds plans had slightly worse dose metrics to organs at risk than SBRT plans. Trx-5fds achieved superior dosimetry robustness for iCTV, esophagus, and spinal cord doses than both Trx-3fds and conventional SBRT plans. There was no significant difference in dose rate robustness for V(40Gy/s) coverage between Trx-3fds and Trx-5fds. Dose rate distribution has similar distributions to the dose when perturbation exists. CONCLUSION: Transmission plans yield overall modestly inferior plan quality compared to the conventional proton SBRT plans but provide improved robustness and the potential for a toxicity-sparing FLASH effect. By using more beams (5- versus 3-field), both dose and dose rate robustness for transmission plans can be achieved. |
format | Online Article Text |
id | pubmed-9435957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94359572022-09-02 Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer Wei, Shouyi Lin, Haibo Huang, Sheng Shi, Chengyu Xiong, Weijun Zhai, Huifang Hu, Lei Yu, Gang Press, Robert H. Hasan, Shaakir Chhabra, Arpit M. Choi, J. Isabelle Simone, Charles B. Kang, Minglei Front Oncol Oncology PURPOSES: To evaluate the plan quality and robustness of both dose and dose rate of proton pencil beam scanning (PBS) transmission FLASH delivery in lung cancer treatment. METHODS AND MATERIALS: An in-house FLASH planning platform was used to optimize 10 lung cancer patients previously consecutively treated with proton stereotactic body radiation therapy (SBRT) to receive 3 and 5 transmission beams (Trx-3fds and Trx-5fds, respectively) to 34 Gy in a single fraction. Perturbation scenarios (n=12) for setup and range uncertainties (5 mm and 3.5%) were introduced, and dose-volume histogram and dose-rate-volume histogram bands were generated. Conventional proton SBRT clinical plans were used as a reference. RTOG 0915 dose metrics and 40 Gy/s dose rate coverage (V(40Gy/s)) were used to assess the dose and dose rate robustness. RESULTS: Trx-5fds yields a comparable iCTV D(2%) of 105.3%, whereas Trx-3fds resulted in inferior D(2%) of 111.9% to the clinical SBRT plans with D(2%) of 105.6% (p<0.05). Both Trx-5fds and Trx-3fds plans had slightly worse dose metrics to organs at risk than SBRT plans. Trx-5fds achieved superior dosimetry robustness for iCTV, esophagus, and spinal cord doses than both Trx-3fds and conventional SBRT plans. There was no significant difference in dose rate robustness for V(40Gy/s) coverage between Trx-3fds and Trx-5fds. Dose rate distribution has similar distributions to the dose when perturbation exists. CONCLUSION: Transmission plans yield overall modestly inferior plan quality compared to the conventional proton SBRT plans but provide improved robustness and the potential for a toxicity-sparing FLASH effect. By using more beams (5- versus 3-field), both dose and dose rate robustness for transmission plans can be achieved. Frontiers Media S.A. 2022-08-15 /pmc/articles/PMC9435957/ /pubmed/36059710 http://dx.doi.org/10.3389/fonc.2022.970602 Text en Copyright © 2022 Wei, Lin, Huang, Shi, Xiong, Zhai, Hu, Yu, Press, Hasan, Chhabra, Choi, Simone and Kang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wei, Shouyi Lin, Haibo Huang, Sheng Shi, Chengyu Xiong, Weijun Zhai, Huifang Hu, Lei Yu, Gang Press, Robert H. Hasan, Shaakir Chhabra, Arpit M. Choi, J. Isabelle Simone, Charles B. Kang, Minglei Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer |
title | Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer |
title_full | Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer |
title_fullStr | Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer |
title_full_unstemmed | Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer |
title_short | Dose rate and dose robustness for proton transmission FLASH-RT treatment in lung cancer |
title_sort | dose rate and dose robustness for proton transmission flash-rt treatment in lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435957/ https://www.ncbi.nlm.nih.gov/pubmed/36059710 http://dx.doi.org/10.3389/fonc.2022.970602 |
work_keys_str_mv | AT weishouyi doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT linhaibo doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT huangsheng doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT shichengyu doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT xiongweijun doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT zhaihuifang doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT hulei doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT yugang doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT pressroberth doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT hasanshaakir doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT chhabraarpitm doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT choijisabelle doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT simonecharlesb doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer AT kangminglei doserateanddoserobustnessforprotontransmissionflashrttreatmentinlungcancer |